Replies to post #219130 on Biotech Values

[DewDiligence]

SNDX, NKTR ink clinical-trial collaboration for Entinostat/NKTR-214 in second-lime melanoma:

https://www.prnewswire.com/news-releases/syndax-and-nektar-therapeutics-announce-immuno-oncology-clinical-trial-collaboration-300656793.html

NKTR is furnishing free drug for the phase-1/2 clinical trial, but no cash.

[DewDiligence]

On today's CC, SNDX said that enrollment was 98% complete as of July 31. Hence, SNDX may (barely) meet its guidance of completing enrollment and reporting the results of the PFS analysis during 3Q18.